pharmaphorum
JANUARY 25, 2023
BMS’ lawsuit claims that Imjudo (tremelimumab) infringes two patents covering its own CTLA4 drug Yervoy (ipilimumab), which has been on the market since 2011 and is a key component of combination therapies for cancer with BMS’ PD-1 inhibitor Opdivo (nivolumab).
pharmaphorum
APRIL 27, 2021
On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 21, 2021
The EMA has cleared Onureg (formerly CC-486) as the first-ever orally-active drug that can be used for frontline maintenance treatment of AML who are in remission after initial chemotherapy but are not eligible for potentially curative therapies like a stem cell transplant. months from 14.8 months in a placebo-treated group.
Pharmaceutical Technology
SEPTEMBER 13, 2022
Since the approval of the first ICI – Bristol-Myers Squibb's (BMS) Yervoy (ipilimumab) in 2011 for unresectable metastatic melanoma – multiple checkpoint inhibitors have been approved in this disease setting. month progression-free survival (PFS) benefit over SOC chemotherapy. MSI-H/dMMR CRC accounts for 10-15% of all CRC.
pharmaphorum
JUNE 23, 2021
Savolitinib will be sold as Orpathys for the treatment of NSCLC patients whose tumours have MET exon 14 skipping mutations who have previously had systemic treatment or are unable to receive chemotherapy. Savolitinib was discovered by HutchMed (formerly Hutchison China Meditech) and has been partnered by AZ since 2011.
RX Note
AUGUST 4, 2023
You may also refresh knowledge of clinical pharmacokinetics , total parenteral nutrition or chemotherapy before entering the relevant rotations. You should be at least familiar with insulin and inhalers counselling before entering ward, inpatient or outpatient. What to do if I did not know the answer to questions from patients or doctors?
STAT
SEPTEMBER 13, 2023
plummeted nearly 45% between 2011 and 2019, new federal data show, even as fatal overdoses rose to record levels as users increasingly used heroin, and then illegal fentanyl, The Washington Post reports. Once again, we hope you have a successful day and, of course, keep in touch. We enjoy hearing your tips and tidbits.
Expert insights. Personalized for you.
52 
Let's personalize your content